Acelyrin, Inc.

The proposed all-stock merger of troubled Acelyrin with Alumis, first announced on 6 February, will go forward, Acelyrin said 4 March, stating it will decline an unsolicited acquisition offer from Tan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Alumis stands to bulk up its financial position as well as its portfolio of drugs to treat immune-mediated diseases through its merger with Acelyrin. But while analysts saw the deal as a positive from

A month after shelving its previous lead drug candidate, izokibep, Acelyrin said on 6 January that it is moving lonigutamab into Phase III in thyroid eye disease with a revised dosing regimen from Pha